These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 27639083)

  • 1. Population Pharmacokinetics and Pharmacodynamics of the Calcimimetic Etelcalcetide in Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis.
    Chen P; Olsson Gisleskog P; Perez-Ruixo JJ; Xiao J; Wilkins J; Narayanan A; Gibbs JP; Melhem M
    CPT Pharmacometrics Syst Pharmacol; 2016 Sep; 5(9):484-94. PubMed ID: 27639083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population Pharmacokinetic and Pharmacodynamic Modeling of Etelcalcetide in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis.
    Chen P; Narayanan A; Wu B; Gisleskog PO; Gibbs JP; Chow AT; Melhem M
    Clin Pharmacokinet; 2018 Jan; 57(1):71-85. PubMed ID: 28508378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: Two Randomized Clinical Trials.
    Block GA; Bushinsky DA; Cunningham J; Drueke TB; Ketteler M; Kewalramani R; Martin KJ; Mix TC; Moe SM; Patel UD; Silver J; Spiegel DM; Sterling L; Walsh L; Chertow GM
    JAMA; 2017 Jan; 317(2):146-155. PubMed ID: 28097355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial.
    Block GA; Bushinsky DA; Cheng S; Cunningham J; Dehmel B; Drueke TB; Ketteler M; Kewalramani R; Martin KJ; Moe SM; Patel UD; Silver J; Sun Y; Wang H; Chertow GM
    JAMA; 2017 Jan; 317(2):156-164. PubMed ID: 28097356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacology of Parsabiv
    Harada K; Fujioka A; Konno M; Inoue A; Yamada H; Hirota Y
    Eur J Pharmacol; 2019 Jan; 842():139-145. PubMed ID: 30342948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Pharmacokinetics and Pharmacodynamics of Etelcalcetide, a Novel Calcimimetic for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on Hemodialysis.
    Wu B; Melhem M; Subramanian R; Chen P; Jaramilla Sloey B; Fouqueray B; Hock MB; Skiles GL; Chow AT; Lee E
    J Clin Pharmacol; 2018 Jun; 58(6):717-726. PubMed ID: 29534286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism.
    Bushinsky DA; Chertow GM; Cheng S; Deng H; Kopyt N; Martin KJ; Rastogi A; Ureña-Torres P; Vervloet M; Block GA
    Nephrol Dial Transplant; 2020 Oct; 35(10):1769-1778. PubMed ID: 30859218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of secondary hyperparathyroidism in patients on hemodialysis using a novel synthetic peptide calcimimetic, etelcalcetide: a short-term clinical study.
    Mima A; Tansho K; Nagahara D; Watase K
    J Int Med Res; 2018 Nov; 46(11):4578-4585. PubMed ID: 30027791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved Control of Secondary Hyperparathyroidism in Hemodialysis Patients Switching from Oral Cinacalcet to Intravenous Etelcalcetide, Especially in Nonadherent Patients.
    Xipell M; Montagud-Marrahi E; Rubio MV; Ojeda R; Arias-Guillén M; Fontseré N; Rodas L; Vera M; Broseta JJ; Torregrosa V; Filella X; Maduell F
    Blood Purif; 2019; 48(2):106-114. PubMed ID: 30699421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemodialysis patients.
    Fukagawa M; Yokoyama K; Shigematsu T; Akiba T; Fujii A; Kuramoto T; Odani M; Akizawa T;
    Nephrol Dial Transplant; 2017 Oct; 32(10):1723-1730. PubMed ID: 28057872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug disposition model of radiolabeled etelcalcetide in patients with chronic kidney disease and secondary hyperparathyroidism on hemodialysis.
    Wu L; Melhem M; Subramanian R; Wu B
    J Pharmacokinet Pharmacodyn; 2017 Feb; 44(1):43-53. PubMed ID: 28063122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 1, single-dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of etelcalcetide in pediatric patients with secondary hyperparathyroidism receiving hemodialysis.
    Sohn W; Salusky IB; Schmitt CP; Taylan C; Walle JV; Ngang J; Yan L; Kroenke M; Warady BA
    Pediatr Nephrol; 2021 Jan; 36(1):133-142. PubMed ID: 32647975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An integrated analysis of safety and tolerability of etelcalcetide in patients receiving hemodialysis with secondary hyperparathyroidism.
    Block GA; Chertow GM; Sullivan JT; Deng H; Mather O; Tomlin H; Serenko M
    PLoS One; 2019; 14(3):e0213774. PubMed ID: 30875390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Etelcalcetide (AMG 416), a peptide agonist of the calcium-sensing receptor, preserved cortical bone structure and bone strength in subtotal nephrectomized rats with established secondary hyperparathyroidism.
    Li X; Yu L; Asuncion F; Grisanti M; Alexander S; Hensley K; Han CY; Niu QT; Dwyer D; Villasenor K; Stolina M; Dean C; Ominsky MS; Ke HZ; Tomlinson JE; Richards WG
    Bone; 2017 Dec; 105():163-172. PubMed ID: 28867373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of etelcalcetide, an intravenous calcimimetic, for up to 52 weeks in hemodialysis patients with secondary hyperparathyroidism: results of a post-marketing surveillance in Japan.
    Yokoyama K; Fukagawa M; Shigematsu T; Akiba T; Yoshikawa K; Tsuchiya A; Kuwabara M; Akizawa T
    Clin Exp Nephrol; 2021 Jan; 25(1):66-79. PubMed ID: 32816132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Etelcalcetide for the treatment of secondary hyperparathyroidism.
    Hamano N; Komaba H; Fukagawa M
    Expert Opin Pharmacother; 2017 Apr; 18(5):529-534. PubMed ID: 28277829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of the Intravenous Calcimimetic Etelcalcetide on Bone Turnover and Serum Fibroblast Growth Factor 23: Post Hoc Analysis of an Open-label Study.
    Shigematsu T; Fukagawa M; Yokoyama K; Akiba T; Fujii A; Odani M; Akizawa T
    Clin Ther; 2018 Dec; 40(12):2099-2111. PubMed ID: 30473399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring the potential value of improved care for secondary hyperparathyroidism with a novel calcimimetic therapy.
    Stollenwerk B; Iannazzo S; Cooper K; Belozeroff V
    J Med Econ; 2017 Oct; 20(10):1110-1115. PubMed ID: 28803497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Effects of Etelcalcetide and Maxacalcitol on Serum Calcification Propensity in Secondary Hyperparathyroidism: A Randomized Clinical Trial.
    Shoji T; Nakatani S; Kabata D; Mori K; Shintani A; Yoshida H; Takahashi K; Ota K; Fujii H; Ueda S; Nishi S; Nakatani T; Yoshiyama M; Goto K; Hamada T; Imanishi M; Ishimura E; Kagitani S; Kato Y; Kumeda Y; Maekawa K; Matsumura T; Nagayama H; Obi Y; Ohno Y; Sai Y; Sakurai M; Sasaki S; Shidara K; Shoji S; Tsujimoto Y; Yamakawa K; Yasuda H; Yodoi S; Inaba M; Emoto M
    Clin J Am Soc Nephrol; 2021 Apr; 16(4):599-612. PubMed ID: 33685864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Etelcalcetide: injectable calcimimetic for the treatment of secondary hyperparathyroidism in hemodialysis-dependent patients.
    Ureña Torres PA; Bover J; Cohen-Solal M
    Drugs Today (Barc); 2017 Sep; 53(9):489-500. PubMed ID: 29238762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.